Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on June 28, 2017, covering events occurring on June 28 and June 29, 2017. The filing addresses corporate governance changes, specifically the election of a new director and an amendment to the company's by-laws.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
- Board Composition: The Board of Directors was expanded from eleven to twelve members, effective June 29, 2017.
- Director Election: John G. Stratton was named to the Board of Directors, effective immediately on June 29, 2017.
- By-Law Amendment: Article III, Section 2 of the By-Laws was amended to reflect the new board size.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the announcement of the director election and by-law amendment.
Key Facts for Investor Verification
- Verify the effective date of John G. Stratton's appointment to the Board (June 29, 2017).
- Confirm the updated total number of directors on the Board (12).
- Review the amended By-Laws (Exhibit 3.1) for the specific language change in Article III, Section 2.